HK1109406A1 - Rnai modulation of apob and uses thereof - Google Patents
Rnai modulation of apob and uses thereofInfo
- Publication number
- HK1109406A1 HK1109406A1 HK08100094.7A HK08100094A HK1109406A1 HK 1109406 A1 HK1109406 A1 HK 1109406A1 HK 08100094 A HK08100094 A HK 08100094A HK 1109406 A1 HK1109406 A1 HK 1109406A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- apob
- rnai modulation
- rnai
- modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US61314104P | 2004-09-24 | 2004-09-24 | |
PCT/US2005/034492 WO2006036916A2 (en) | 2004-09-24 | 2005-09-26 | Rnai modulation of apob and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1109406A1 true HK1109406A1 (en) | 2008-06-06 |
Family
ID=36119510
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08100094.7A HK1109406A1 (en) | 2004-09-24 | 2008-01-04 | Rnai modulation of apob and uses thereof |
Country Status (9)
Country | Link |
---|---|
US (5) | US7528118B2 (zh) |
EP (4) | EP2377873B1 (zh) |
JP (2) | JP5883205B2 (zh) |
CN (2) | CN102628044A (zh) |
AU (1) | AU2005289588B2 (zh) |
CA (2) | CA2848573A1 (zh) |
HK (1) | HK1109406A1 (zh) |
NZ (4) | NZ586217A (zh) |
WO (1) | WO2006036916A2 (zh) |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030166282A1 (en) | 2002-02-01 | 2003-09-04 | David Brown | High potency siRNAS for reducing the expression of target genes |
EP3415625A1 (en) | 2002-02-01 | 2018-12-19 | Life Technologies Corporation | Double-stranded oligonucleotides |
US20060009409A1 (en) | 2002-02-01 | 2006-01-12 | Woolf Tod M | Double-stranded oligonucleotides |
ATE536418T1 (de) | 2004-06-07 | 2011-12-15 | Protiva Biotherapeutics Inc | Lipidverkapselte interferenz-rna |
AU2005251403B2 (en) * | 2004-06-07 | 2011-09-01 | Arbutus Biopharma Corporation | Cationic lipids and methods of use |
WO2006002538A1 (en) * | 2004-07-02 | 2006-01-12 | Protiva Biotherapeutics, Inc. | Immunostimulatory sirna molecules and uses therefor |
CA2587411A1 (en) * | 2004-11-17 | 2006-05-26 | Protiva Biotherapeutics, Inc. | Sirna silencing of apolipoprotein b |
US20070054873A1 (en) * | 2005-08-26 | 2007-03-08 | Protiva Biotherapeutics, Inc. | Glucocorticoid modulation of nucleic acid-mediated immune stimulation |
AU2006291836B2 (en) * | 2005-09-15 | 2012-02-23 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-Bl00 expression |
EP2395012B8 (en) * | 2005-11-02 | 2018-06-06 | Arbutus Biopharma Corporation | Modified siRNA molecules and uses thereof |
CA2649045C (en) | 2006-04-03 | 2019-06-11 | Santaris Pharma A/S | Pharmaceutical composition comprising anti-mirna antisense oligonucleotides |
NZ571569A (en) | 2006-04-03 | 2011-09-30 | Santaris Pharma As | Pharmaceutical compositions comprising anti miRNA antisense oligonucleotides |
US7915399B2 (en) * | 2006-06-09 | 2011-03-29 | Protiva Biotherapeutics, Inc. | Modified siRNA molecules and uses thereof |
JP2008220366A (ja) * | 2007-02-16 | 2008-09-25 | National Institute Of Advanced Industrial & Technology | 修飾型pna/rna複合体 |
WO2008113830A1 (en) | 2007-03-22 | 2008-09-25 | Santaris Pharma A/S | Rna antagonist compounds for the inhibition of apo-b100 expression |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
EP2173358B1 (en) * | 2007-06-22 | 2015-10-21 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
WO2009043353A2 (en) | 2007-10-04 | 2009-04-09 | Santaris Pharma A/S | Micromirs |
US8404659B2 (en) | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
EP2315832B1 (en) | 2008-08-01 | 2015-04-08 | Roche Innovation Center Copenhagen A/S | Micro-rna mediated modulation of colony stimulating factors |
CN104119242B (zh) | 2008-10-09 | 2017-07-07 | 泰米拉制药公司 | 改善的氨基脂质和递送核酸的方法 |
EP2184054A1 (en) | 2008-11-08 | 2010-05-12 | Lipoxen Technologies Limited | Small Interfering RNA Delivery |
KR101829469B1 (ko) | 2008-12-04 | 2018-03-30 | 큐알엔에이, 인크. | Epo에 대한 천연 안티센스 전사체의 억제에 의해 에리트로포에틴(epo) 관련된 질환의 치료 |
WO2010076248A1 (en) * | 2008-12-31 | 2010-07-08 | Santaris Pharma A/S | Use of lna apob antisense oligomers for the treatment of acute coronary syndromes |
WO2010108140A1 (en) * | 2009-03-20 | 2010-09-23 | Alios Biopharma, Inc. | Substituted nucleoside and nucleotide analogs |
ES2599979T3 (es) | 2009-04-24 | 2017-02-06 | Roche Innovation Center Copenhagen A/S | Composiciones farmacéuticas para el tratamiento de pacientes de VHC que no responden al interferón |
WO2010141511A2 (en) * | 2009-06-01 | 2010-12-09 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotides for multivalent rna interference, compositions and methods of use thereof |
ES2613498T3 (es) | 2009-07-01 | 2017-05-24 | Protiva Biotherapeutics Inc. | Nuevas formulaciones de lípidos para el suministro de agentes terapéuticos a tumores sólidos |
WO2011000106A1 (en) | 2009-07-01 | 2011-01-06 | Protiva Biotherapeutics, Inc. | Improved cationic lipids and methods for the delivery of therapeutic agents |
US9018187B2 (en) | 2009-07-01 | 2015-04-28 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods for the delivery of therapeutic agents |
US8236943B2 (en) * | 2009-07-01 | 2012-08-07 | Protiva Biotherapeutics, Inc. | Compositions and methods for silencing apolipoprotein B |
WO2011009697A1 (en) | 2009-07-21 | 2011-01-27 | Santaris Pharma A/S | Antisense oligomers targeting pcsk9 |
US20130079382A1 (en) | 2009-10-12 | 2013-03-28 | Larry J. Smith | Methods and Compositions for Modulating Gene Expression Using Oligonucleotide Based Drugs Administered in vivo or in vitro |
JP2011155914A (ja) * | 2010-02-01 | 2011-08-18 | Osaka Univ | 脂質異常症治療薬剤としての化学修飾siRNA |
JP2013528665A (ja) | 2010-03-26 | 2013-07-11 | メルサナ セラピューティックス, インコーポレイテッド | ポリヌクレオチドの送達のための修飾ポリマー、その製造方法、およびその使用方法 |
WO2011141703A1 (en) * | 2010-05-12 | 2011-11-17 | Protiva Biotherapeutics Inc. | Compositions and methods for silencing apolipoprotein b |
CN105061534A (zh) | 2010-09-22 | 2015-11-18 | 艾丽奥斯生物制药有限公司 | 取代的核苷酸类似物 |
KR101328568B1 (ko) | 2010-10-22 | 2013-11-13 | 성균관대학교산학협력단 | Rna 간섭을 유도하는 핵산 분자 및 그 용도 |
WO2012091496A2 (en) * | 2010-12-30 | 2012-07-05 | Samyang Biopharmaceuticals Corporation | siRNA FOR INHIBITION OF Hif1α EXPRESSION AND ANTICANCER COMPOSITION CONTAINING THE SAME |
EP2699271A4 (en) | 2011-04-20 | 2015-10-07 | Larry J Smith | METHODS AND COMPOSITIONS FOR MODULATING GENE EXPRESSION USING COMPONENTS THAT SELF-ASSEMBLED IN CELLS AND PRODUCE RNAI ACTIVITY |
MX359548B (es) * | 2011-11-18 | 2018-10-02 | Alnylam Pharmaceuticals Inc | Agentes de iarn modificados. |
AU2012358804B2 (en) | 2011-12-22 | 2018-04-19 | Alios Biopharma, Inc. | Substituted phosphorothioate nucleotide analogs |
EP3988104A1 (en) | 2012-02-24 | 2022-04-27 | Arbutus Biopharma Corporation | Trialkyl cationic lipids and methods of use thereof |
US8916538B2 (en) | 2012-03-21 | 2014-12-23 | Vertex Pharmaceuticals Incorporated | Solid forms of a thiophosphoramidate nucleotide prodrug |
NZ630805A (en) | 2012-03-22 | 2016-01-29 | Alios Biopharma Inc | Pharmaceutical combinations comprising a thionucleotide analog |
EP3514236A1 (en) * | 2012-05-22 | 2019-07-24 | Olix Pharmaceuticals, Inc. | Rna-interference-inducing nucleic acid molecule able to penetrate into cells, and use therefor |
CN104884618A (zh) | 2012-11-15 | 2015-09-02 | 罗氏创新中心哥本哈根有限公司 | 寡核苷酸缀合物 |
EP3591054A1 (en) | 2013-06-27 | 2020-01-08 | Roche Innovation Center Copenhagen A/S | Antisense oligomers and conjugates targeting pcsk9 |
AU2016257996A1 (en) * | 2015-05-06 | 2017-10-26 | Alnylam Pharmaceuticals, Inc. | Factor XII (Hageman Factor) (F12), Kallikrein B, Plasma (Fletcher Factor) 1 (KLKB1), and Kininogen 1 (KNG1) iRNA compositions and methods of use thereof |
AU2016312530A1 (en) | 2015-08-24 | 2018-03-01 | Halo-Bio Rnai Therapeutics, Inc. | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
CN108699556B (zh) | 2015-11-16 | 2023-02-17 | 奥利克斯医药有限公司 | 使用靶向myd88或tlr3的rna复合物治疗老年性黄斑变性 |
EP3411481A4 (en) | 2016-02-02 | 2020-02-26 | Olix Pharmaceuticals, Inc. | TREATMENT OF DISEASES ASSOCIATED WITH ANGIOGENESIS USING ANGPT2 AND PDGFB TARGETED RNA COMPLEXES |
JP6944942B2 (ja) | 2016-02-02 | 2021-10-06 | オリックス ファーマシューティカルズ,インコーポレーテッド | IL4Rα、TRPA1、またはF2RL1を標的とするRNA複合体を用いたアトピー性皮膚炎および喘息の治療 |
KR101916652B1 (ko) | 2016-06-29 | 2018-11-08 | 올릭스 주식회사 | 작은 간섭 rna의 rna 간섭효과 증진용 화합물 및 이의 용도 |
JP7244424B2 (ja) * | 2017-01-18 | 2023-03-22 | アルニラム ファーマスーティカルズ インコーポレイテッド | エンドソーム切断可能なリンカー |
EP3580339A4 (en) | 2017-02-10 | 2020-12-23 | Research & Business Foundation Sungkyunkwan University | LONG DOUBLE STRAND RNA FOR RNA INTERFERENCE |
CN110115770B (zh) * | 2019-04-09 | 2023-05-26 | 广州艾迪基因科技有限责任公司 | 一种防治丙型病毒性肝炎的新靶点及其CRISPR-Cas9靶向系统与应用 |
GB2585278B (en) * | 2019-07-02 | 2022-03-16 | Argonaute Rna Ltd | Apolipoprotein B Antagonist |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5328470A (en) | 1989-03-31 | 1994-07-12 | The Regents Of The University Of Michigan | Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor |
IT1274573B (it) | 1995-05-25 | 1997-07-17 | Sits Soc It Telecom Siemens | Processo di fabbricazione di moduli circuitali ibridi includenti dispositivi elettronici in chip |
CA2220950A1 (en) | 1995-05-26 | 1996-11-28 | Somatix Therapy Corporation | Delivery vehicles comprising stable lipid/nucleic acid complexes |
US5898031A (en) * | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
US6245427B1 (en) | 1998-07-06 | 2001-06-12 | DüZGüNES NEJAT | Non-ligand polypeptide and liposome complexes as intracellular delivery vehicles |
US6544743B1 (en) * | 1999-09-17 | 2003-04-08 | Mcgill University | Peroxisome proliferator-activated receptor alpha and disorders of lipid metabolism |
US20070026394A1 (en) * | 2000-02-11 | 2007-02-01 | Lawrence Blatt | Modulation of gene expression associated with inflammation proliferation and neurite outgrowth using nucleic acid based technologies |
CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
US20030170891A1 (en) * | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7407943B2 (en) | 2001-08-01 | 2008-08-05 | Isis Pharmaceuticals, Inc. | Antisense modulation of apolipoprotein B expression |
US7923547B2 (en) * | 2002-09-05 | 2011-04-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
WO2004044140A2 (en) * | 2002-11-05 | 2004-05-27 | Isis Pharmaceticals, Inc. | 2’-substituted oligomeric compounds and compositions for use in gene modulations |
EP1569695B1 (en) * | 2002-11-13 | 2013-05-15 | Genzyme Corporation | Antisense modulation of apolipoprotein b expression |
ATE517992T1 (de) * | 2002-11-14 | 2011-08-15 | Dharmacon Inc | Funktionelle und hyperfunktionelle sirna |
WO2004064737A2 (en) | 2003-01-17 | 2004-08-05 | Alnylam Pharmaceuticals | Therapeutics compositions |
WO2004090108A2 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | Irna conjugates |
WO2004080406A2 (en) * | 2003-03-07 | 2004-09-23 | Alnylam Pharmaceuticals | Therapeutic compositions |
AU2004229519B2 (en) * | 2003-04-09 | 2011-07-21 | Alnylam Pharmaceuticals, Inc. | iRNA conjugates |
EP2666858A1 (en) | 2003-04-17 | 2013-11-27 | Alnylam Pharmaceuticals Inc. | Modified iRNA agents |
CA2522349A1 (en) | 2003-04-17 | 2004-11-04 | Alnylam Pharmaceuticals, Inc. | Protected monomers |
US7004629B2 (en) | 2003-07-26 | 2006-02-28 | Arthur Joseph Shrader | Method and apparatus for hanging a resealable bag |
AU2005230684B2 (en) | 2004-04-05 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Process and reagents for oligonucleotide synthesis and purification |
EP1765847A4 (en) * | 2004-05-27 | 2010-10-20 | Alnylam Pharmaceuticals Inc | NUCLEASERESISTENT DOUBLE-STRANDED RIBONUCLEIC ACID |
CA2576233C (en) * | 2004-08-10 | 2016-03-15 | Alnylam Pharmaceuticals, Inc. | Conjugate comprising an antagomir and a ligand |
CA2603730A1 (en) * | 2005-03-31 | 2006-10-05 | Calando Pharmaceuticals, Inc. | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
EP2008274B1 (en) * | 2006-03-31 | 2015-05-27 | Alnylam Pharmaceuticals Inc. | Compositions and methods for inhibiting expression of eg5 gene |
US8598333B2 (en) * | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
WO2010147992A1 (en) | 2009-06-15 | 2010-12-23 | Alnylam Pharmaceuticals, Inc. | Methods for increasing efficacy of lipid formulated sirna |
-
2005
- 2005-09-26 EP EP11004573.9A patent/EP2377873B1/en active Active
- 2005-09-26 NZ NZ586217A patent/NZ586217A/en unknown
- 2005-09-26 EP EP15166978.5A patent/EP2982754A1/en not_active Withdrawn
- 2005-09-26 AU AU2005289588A patent/AU2005289588B2/en active Active
- 2005-09-26 CN CN2012100807933A patent/CN102628044A/zh active Pending
- 2005-09-26 EP EP05802154A patent/EP1802644B1/en active Active
- 2005-09-26 NZ NZ554214A patent/NZ554214A/en active IP Right Revival
- 2005-09-26 CA CA2848573A patent/CA2848573A1/en not_active Abandoned
- 2005-09-26 JP JP2007533724A patent/JP5883205B2/ja active Active
- 2005-09-26 EP EP20110004574 patent/EP2380897B1/en active Active
- 2005-09-26 NZ NZ583290A patent/NZ583290A/en unknown
- 2005-09-26 NZ NZ572403A patent/NZ572403A/en unknown
- 2005-09-26 CA CA2580707A patent/CA2580707C/en active Active
- 2005-09-26 US US11/235,385 patent/US7528118B2/en active Active
- 2005-09-26 CN CN2005800402969A patent/CN101133074B/zh active Active
- 2005-09-26 WO PCT/US2005/034492 patent/WO2006036916A2/en active Application Filing
-
2008
- 2008-01-04 HK HK08100094.7A patent/HK1109406A1/xx unknown
-
2009
- 2009-03-09 US US12/400,744 patent/US7723317B2/en active Active
-
2010
- 2010-03-19 US US12/728,139 patent/US8188061B2/en active Active
-
2012
- 2012-04-19 US US13/450,886 patent/US8592571B2/en active Active
- 2012-12-18 JP JP2012275867A patent/JP2013075903A/ja active Pending
-
2013
- 2013-10-21 US US14/058,679 patent/US9187747B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1109406A1 (en) | Rnai modulation of apob and uses thereof | |
EP1896084A4 (en) | RNAI MODULATION OF HIF-1 AND THERAPEUTIC APPLICATIONS THEREOF | |
EP1751124A4 (en) | RAF MODULATORS AND METHODS OF USE | |
HK1204903A1 (zh) | 縫合方法和器械 | |
IL213843A0 (en) | 4-aminotetracyclines and methods of use thereof | |
EP1773857A4 (en) | THE IMMUNE SYSTEM STIMULATING SIRNA MOLECULES AND APPLICATIONS THEREOF | |
EP1718602A4 (en) | THERAPEUTIC AND CARRIER MOLECULES | |
EP1993611A4 (en) | RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES | |
IL212978A0 (en) | Micrornas and uses thereof | |
HK1126785A1 (zh) | 修飾的 分子及其應用 | |
PT2371958E (pt) | Novos sirna e métodos para a sua utilização | |
EP1802588A4 (en) | SUBSTITUTED AMINOPYRIMIDONE AND APPLICATIONS THEREOF | |
IL182554A0 (en) | Anti-addl antibodies and uses thereof | |
EP1909644A4 (en) | INSERTION APPARATUS AND METHODS OF USE | |
EP2069380A4 (en) | RNAI MODULATION OF SCAP AND ITS THERAPEUTIC USE | |
IL176958A0 (en) | Compounds and methods of use | |
EP1729710A4 (en) | METHODS AND APPARATUSES FOR REHABILITATION OF THE MARKET | |
EP1913112A4 (en) | SUPPORTING AGENT AND METHODS OF USE | |
EP1909850A4 (en) | RNAI MODULATION OF RHO-A GENE AND USES THEREOF | |
IL179497A0 (en) | Carboranylporphyrins and uses thereof | |
EP1853632A4 (en) | MODIFICATION OF AMINES AND ALCOHOLS | |
GB0411861D0 (en) | Authentication of applications | |
ZA200703406B (en) | Anti-ADDL antibodies and uses thereof | |
EP1891407A4 (en) | ACCELERATION DEVICES AND METHODS OF USE THEREOF | |
IL180365A0 (en) | Carboranylporphyrins and uses thereof |